How many men are really benefiting from genome-targeted prostate cancer treatment?

The answer to that question, at present, is that we don’t know — but it’s probably very few indeed compared to all the men who have progressive forms of prostate cancer. … READ MORE …

More from the EAU annual meeting in Munich

UroToday has provided a second set of reports on the key presentations given at the annual meeting of the European Association of Urology, being held this year in Munich, Germany. … READ MORE …